Furthermore, as LIR and VPA have shown promising results against WS progression and the ability to affect RAAS components, the rats were treated with LIR, VPA or their combination for eight consecutive days to evaluate whether those compounds act by modulating the RAAS and bradykinin pathways in Wfs1 deficiency. Here, WFS1 is linked to Werner syndrome.